Literature DB >> 33512531

Genotype-Phenotype Correlation in Fibrous Dysplasia/McCune-Albright Syndrome.

Maria Zhadina1, Kelly L Roszko1, Raya E S Geels2, Luis F de Castro1, Michael T Collins1, Alison M Boyce1,3.   

Abstract

CONTEXT: Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare bone and endocrine disorder resulting in fractures, pain, and disability. There are no targeted or effective therapies to alter the disease course. Disease arises from somatic gain-of-function variants at the R201 codon in GNAS, replacing arginine by either cysteine or histidine. The relative pathogenicity of these variants is not fully understood.
OBJECTIVE: This work aimed 1) to determine whether the most common GNAS variants (R201C and R201H) are associated with a specific clinical phenotype, and 2) to determine the prevalence of the most common GNAS variants in a large patient cohort.
METHODS: This retrospective cross-sectional analysis measured the correlation between genotype and phenotype characterized by clinical, biochemical, and radiographic data.
RESULTS: Sixty-one individuals were genotyped using DNA extracted from tissue or circulating cell-free DNA. Twenty-two patients (36.1%) had the R201C variant, and 39 (63.9%) had the R201H variant. FD skeletal disease burden, hypophosphatemia prevalence, fracture incidence, and ambulation status were similar between the 2 groups. There was no difference in the prevalence of endocrinopathies, ultrasonographic gonadal or thyroid abnormalities, or pancreatic involvement. There was a nonsignificant association of cancer with the R201H variant.
CONCLUSION: There is no clear genotype-phenotype correlation in patients with the most common FD/MAS pathogenic variants. The predominance of the R201H variant observed in our cohort and reported in the literature indicates it is likely responsible for a larger burden of disease in the overall population of patients with FD/MAS, which may have important implications for the future development of targeted therapies. Published by Oxford University Press on behalf of the Endocrine Society 2021.

Entities:  

Keywords:  G-coupled protein receptors; cell free DNA; metabolic bone disease

Mesh:

Substances:

Year:  2021        PMID: 33512531      PMCID: PMC8522305          DOI: 10.1210/clinem/dgab053

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  The role of type 1 and type 2 5'-deiodinase in the pathophysiology of the 3,5,3'-triiodothyronine toxicosis of McCune-Albright syndrome.

Authors:  Francesco S Celi; Giuseppe Coppotelli; Aaron Chidakel; Marilyn Kelly; Beth A Brillante; Thomas Shawker; Natasha Cherman; Penelope P Feuillan; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

2.  A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone.

Authors:  B D Idowu; M Al-Adnani; P O'Donnell; L Yu; E Odell; T Diss; R E Gale; A M Flanagan
Journal:  Histopathology       Date:  2007-05       Impact factor: 5.087

3.  Increased Prevalence of Malignancies in Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS): Data from a National Referral Center and the Dutch National Pathology Registry (PALGA).

Authors:  M Hagelstein-Rotman; M E Meier; B C J Majoor; A H G Cleven; P D S Dijkstra; N A T Hamdy; M A J van de Sande; O M Dekkers; N M Appelman-Dijkstra
Journal:  Calcif Tissue Int       Date:  2020-11-23       Impact factor: 4.333

4.  Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome.

Authors:  J M Kirk; C E Brain; D J Carson; J C Hyde; D B Grant
Journal:  J Pediatr       Date:  1999-06       Impact factor: 4.406

5.  Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations.

Authors:  Michael T Collins; Nicholas J Sarlis; Maria J Merino; Jason Monroe; Susan E Crawford; Jonathan A Krakoff; Lori C Guthrie; Sandra Bonat; Pamela G Robey; Andrew Shenker
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

6.  Characterization and management of testicular pathology in McCune-Albright syndrome.

Authors:  Alison M Boyce; William H Chong; Thomas H Shawker; Peter A Pinto; W Marsten Linehan; Nisan Bhattacharryya; Maria J Merino; Frederick R Singer; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2012-06-28       Impact factor: 5.958

7.  Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.

Authors:  L S Weinstein; A Shenker; P V Gejman; M J Merino; E Friedman; A M Spiegel
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

8.  Malignancies in fibrous dysplasia.

Authors:  P Ruggieri; F H Sim; J R Bond; K K Unni
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860

9.  Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation.

Authors:  M Riminucci; L W Fisher; A Shenker; A M Spiegel; P Bianco; P Gehron Robey
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

10.  GNAS transcripts in skeletal progenitors: evidence for random asymmetric allelic expression of Gs alpha.

Authors:  Stefano Michienzi; Natasha Cherman; Kenn Holmbeck; Alessia Funari; Michael T Collins; Paolo Bianco; Pamela Gehron Robey; Mara Riminucci
Journal:  Hum Mol Genet       Date:  2007-06-12       Impact factor: 6.150

View more
  2 in total

1.  Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors.

Authors:  Raya E S Geels; Maartje E Meier; Amanda Saikali; Roula Tsonaka; Natasha M Appelman-Dijkstra; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2021-11-17       Impact factor: 6.390

2.  Postoperative thyroid crisis in an 11-year old male with McCune-Albright syndrome and atypical triiodothyronine hyperthyroidism: A case report.

Authors:  Jingen Hu; Caibao Hu
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.